First-Line Japan Alecensa Trial Stopped Early On Benefits
This article was originally published in Scrip
Executive Summary
A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding well for the ALK inhibitor in this important setting.